Researchers develop ultra-sensitive CAR-T cells targeting CD70 for solid tumors and KRASG12V/HLA-A*02:01-specific CAR-T cells for cancers with KRAS mutations, demonstrating efficacy in preclinical models.
Recent advances in chimeric antigen receptor cell therapies highlight improved designs for CAR-T and CAR-NK treatments, with new strategies addressing efficacy and safety challenges in both hematologic and solid tumors.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05489276 |
Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors |
UNKNOWN | PHASE1 |
